Investment case

Liquidia Corporation

LQDA · 15 developments mapped · last assessed 2026-09-14

Market Ontology has mapped 15 macro, policy, and market developments to Liquidia Corporation since 2026-09-03. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

Last close

Unavailable

No published quote

Market cap

Unavailable

Equity value

Diluted shares

Unavailable

Latest reported

Sector

Unavailable

Listing

Unavailable

Filings

Unavailable

No published filing

Valuation

No validated run has been published for LQDA yet, so no modelled value is shown. The LQDA valuation is in the public catch-up queue.

Subscribers do not wait for the weekly cycle: they run LQDA on demand, against live prices and the latest filings, and change any assumption the developments below move.

Filed financials

A validated filed-statement snapshot has not been published for LQDA. Missing data is not estimated or replaced with scenario assumptions.

Continue this research

Value LQDA on your own assumptions

Run the valuation on Liquidia Corporation, change any assumption the events above move, and see the price that falls out.

Public valuations here are refreshed weekly and only published once a run passes every validation check. Subscribers run LQDA on demand instead, against live prices and the latest filings.

Subscribe to value any ticker

Opportunities created

Research workflows

Trade LQDA

Professional

Open trade discovery with Liquidia Corporation and LQDA already in context.

Open

Find pricing gaps in LQDA

Institutional

Open relative-value and arbitrage analysis with LQDA already in context.

Open

Professional actions continue at $399/month. Institutional arbitrage requires the $399/month tier.

$399/month · charged today · cancel anytime. Opens LQDA first, then any listed company you want to value or monitor.

Choose another company

Current case

Strongest support
Liquidia Corp Receives FDA Fast Track Designation for YUTREPIA
Regulatory acceleration, reduced development risk, potential for earlier market entry and increased market access.
2026-09-03 · Moves probability of regulatory approval, time to market, peak sales potential
Open question
Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Litigation Hangs
Direct product adoption vs. legal uncertainty. The patient milestone is positive for product traction, but the ongoing litigation introduces significant downside risk.
2026-09-14 · Moves probability of success for yutrepia, market share penetration for yutrepia, discount rate (due to increased risk)

What changed, by assumption

Probability of success for yutrepia

2026-09-14Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Litigation Hangs
2026-09-13Liquidia Surpasses 5,000 Yutrepia Patient Starts Amid United Therapeutics Patent Battle
2026-09-12Liquidia surpasses 5,000 Yutrepia patients as United Therapeutics litigation looms
2026-09-13Liquidia Surpasses 5,000 Yutrepia Patients Amid United Therapeutics Lawsuit

Probability of commercial success

2026-09-14Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Patent Fight Continues

Yutrepia peak sales estimates

2026-09-12Liquidia Surpasses 5,000 Yutrepia Starts as United Therapeutics Patent Battle Weighs on Stock
2026-09-12Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Litigation Continues
2026-09-13Liquidia Surpasses 5,000 Yutrepia Patients Amid United Therapeutics Patent Suit
2026-09-12Liquidia reaches 5,000 Yutrepia patients as United Therapeutics litigation weighs

Yutrepia peak sales

2026-09-12Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Patent Battle Persists

Market share growth for yutrepia

2026-09-12Liquidia reaches 5,000 Yutrepia patients amid United Therapeutics patent litigation
2026-09-12Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Patent Litigation Lingers

Event impact log

Full ledger →

Date	Mechanism	Direction	Horizon	Impact
2026-09-14	Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Litigation Hangs	mixed	1-3m	0.80
2026-09-14	Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Patent Fight Continues	mixed	3-12m	0.80
2026-09-13	Liquidia Surpasses 5,000 Yutrepia Patients Amid United Therapeutics Lawsuit	mixed	3-12m	0.70
2026-09-13	Liquidia Surpasses 5,000 Yutrepia Patients Amid United Therapeutics Patent Suit	mixed	3-12m	0.70
2026-09-13	Liquidia Surpasses 5,000 Yutrepia Patient Starts Amid United Therapeutics Patent Battle	mixed	3-12m	0.80
2026-09-12	Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Patent Battle Persists	mixed	1-3m	0.80
2026-09-12	Liquidia reaches 5,000 Yutrepia patients as United Therapeutics litigation weighs	mixed	3-12m	0.70
2026-09-12	Liquidia Surpasses 5,000 Yutrepia Starts as United Therapeutics Patent Battle Weighs on Stock	mixed	3-12m	0.80
2026-09-12	Liquidia reaches 5,000 Yutrepia patients amid United Therapeutics patent litigation	mixed	1-3m	0.80
2026-09-12	Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Litigation Continues	mixed	1-3m	0.80
2026-09-12	Liquidia surpasses 5,000 Yutrepia patients as United Therapeutics litigation looms	mixed	1-3m	0.80
2026-09-12	Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Patent Litigation Lingers	mixed	3-12m	0.70

Value LQDA yourself$399/month

Continue this research

Value LQDA on your own assumptions

Run the valuation on Liquidia Corporation, change any assumption the events above move, and see the price that falls out.

Public valuations here are refreshed weekly and only published once a run passes every validation check. Subscribers run LQDA on demand instead, against live prices and the latest filings.

Subscribe to value any ticker

Opportunities created

Research workflows

Trade LQDA

Professional

Open trade discovery with Liquidia Corporation and LQDA already in context.

Open

Find pricing gaps in LQDA

Institutional

Open relative-value and arbitrage analysis with LQDA already in context.

Open

Professional actions continue at $399/month. Institutional arbitrage requires the $399/month tier.

$399/month · charged today · cancel anytime. Opens LQDA first, then any listed company you want to value or monitor.

Choose another company

Liquidia Corporation

LQDA · 15 developments mapped · last assessed 2026-09-14

Value LQDA on your own assumptions

Run the valuation on Liquidia Corporation, change any assumption the events above move, and see the price that falls out.

Public valuations here are refreshed weekly and only published once a run passes every validation check. Subscribers run LQDA on demand instead, against live prices and the latest filings.

Subscribe to value any ticker

Opportunities created

Research workflows

Trade LQDA

Professional

Open trade discovery with Liquidia Corporation and LQDA already in context.

Open

Find pricing gaps in LQDA

Institutional

Open relative-value and arbitrage analysis with LQDA already in context.

Open

Professional actions continue at $399/month. Institutional arbitrage requires the $399/month tier.

$399/month · charged today · cancel anytime. Opens LQDA first, then any listed company you want to value or monitor.

Choose another company

Date

Mechanism

Direction

Horizon

Impact

2026-09-14

Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Litigation Hangs

mixed

1-3m

0.80

2026-09-14

Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Patent Fight Continues

mixed

3-12m

0.80

2026-09-13

Liquidia Surpasses 5,000 Yutrepia Patients Amid United Therapeutics Lawsuit

mixed

3-12m

0.70

2026-09-13

Liquidia Surpasses 5,000 Yutrepia Patients Amid United Therapeutics Patent Suit

mixed

3-12m

0.70

2026-09-13

Liquidia Surpasses 5,000 Yutrepia Patient Starts Amid United Therapeutics Patent Battle

mixed

3-12m

0.80

2026-09-12

Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Patent Battle Persists

mixed

1-3m

0.80

2026-09-12

Liquidia reaches 5,000 Yutrepia patients as United Therapeutics litigation weighs

mixed

3-12m

0.70

2026-09-12

Liquidia Surpasses 5,000 Yutrepia Starts as United Therapeutics Patent Battle Weighs on Stock

mixed

3-12m

0.80

2026-09-12

Liquidia reaches 5,000 Yutrepia patients amid United Therapeutics patent litigation

mixed

1-3m

0.80

2026-09-12

Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Litigation Continues

mixed

1-3m

0.80

2026-09-12

Liquidia surpasses 5,000 Yutrepia patients as United Therapeutics litigation looms

mixed

1-3m

0.80

2026-09-12

Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Patent Litigation Lingers

mixed

3-12m

0.70

Value LQDA on your own assumptions

Run the valuation on Liquidia Corporation, change any assumption the events above move, and see the price that falls out.

Public valuations here are refreshed weekly and only published once a run passes every validation check. Subscribers run LQDA on demand instead, against live prices and the latest filings.

Subscribe to value any ticker

Opportunities created

Research workflows

Trade LQDA

Professional

Open trade discovery with Liquidia Corporation and LQDA already in context.

Open

Find pricing gaps in LQDA

Institutional

Open relative-value and arbitrage analysis with LQDA already in context.

Open

Professional actions continue at $399/month. Institutional arbitrage requires the $399/month tier.

$399/month · charged today · cancel anytime. Opens LQDA first, then any listed company you want to value or monitor.

Choose another company